ID: ALA5281752

Max Phase: Preclinical

Molecular Formula: C21H19NO3

Molecular Weight: 333.39

Associated Items:

Representations

Canonical SMILES:  O=C1/C(=C/c2ccc(N3CCCC3)cc2)Cc2cc3c(cc21)OCO3

Standard InChI:  InChI=1S/C21H19NO3/c23-21-16(10-15-11-19-20(12-18(15)21)25-13-24-19)9-14-3-5-17(6-4-14)22-7-1-2-8-22/h3-6,9,11-12H,1-2,7-8,10,13H2/b16-9+

Standard InChI Key:  MFYJMHRJESJTBE-CXUHLZMHSA-N

Associated Targets(Human)

A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CCD 19Lu (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PANC-1 (6144 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSL Tclin Cathepsin L (3852 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CTSD Tchem Cathepsin D (3201 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 333.39Molecular Weight (Monoisotopic): 333.1365AlogP: 3.84#Rotatable Bonds: 2
Polar Surface Area: 38.77Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 4.83CX LogP: 4.03CX LogD: 4.03
Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.78Np Likeness Score: -0.31

References

1. Altıntop MD, Özdemir A, Temel HE, Demir Cevizlidere B, Sever B, Kaplancıklı ZA, Akalın Çiftçi G..  (2022)  Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer.,  244  [PMID:36270087] [10.1016/j.ejmech.2022.114851]

Source